NASDAQ:ELAB Elevai Labs (ELAB) Stock Price, News & Analysis $0.02 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Elevai Labs Stock (NASDAQ:ELAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Elevai Labs alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.3552-Week Range$0.02▼$4.24Volume241.64 million shsAverage Volume34.02 million shsMarket Capitalization$420,362.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewElevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Read More… What This Post-Election Shift Means for Your Investments (Ad)The election may be over, but its impact on financial markets is only beginning. New trends are emerging, bringing both challenges and opportunities for investors. Many of these changes are flying under the radar, yet they have the potential to reshape the financial landscape for years to come. Understanding how these shifts could affect your wealth—and what steps to take—has never been more important.Click here now to watch the full briefing and prepare for what's next. Elevai Labs Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks7th Percentile Overall ScoreELAB MarketRank™: Elevai Labs scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Elevai Labs. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Elevai Labs is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elevai Labs is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElevai Labs has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Elevai Labs' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted56.82% of the float of Elevai Labs has been sold short.Short Interest Ratio / Days to CoverElevai Labs has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elevai Labs has recently increased by 403.74%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElevai Labs does not currently pay a dividend.Dividend GrowthElevai Labs does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted56.82% of the float of Elevai Labs has been sold short.Short Interest Ratio / Days to CoverElevai Labs has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elevai Labs has recently increased by 403.74%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News SentimentN/A Search Interest24 people have searched for ELAB on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat Follows4 people have added Elevai Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elevai Labs insiders have not sold or bought any company stock.Percentage Held by Insiders37.00% of the stock of Elevai Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.22% of the stock of Elevai Labs is held by institutions.Read more about Elevai Labs' insider trading history. Receive ELAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevai Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address ELAB Stock News HeadlinesCORRECTION - Elevai Labs Inc.November 14, 2024 | globenewswire.comElevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business UpdateNovember 14, 2024 | globenewswire.comWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.November 22, 2024 | InvestorPlace (Ad)Elevai Labs Inc. Announces Update and Extension of Pending Offer to ExchangeNovember 4, 2024 | markets.businessinsider.comElevai Labs Inc. Announces Update and Extension of Pending Offer to ExchangeNovember 4, 2024 | globenewswire.comElevai Biosciences highlights past preclinical data on EL-32October 22, 2024 | markets.businessinsider.comElevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of ObesityOctober 22, 2024 | globenewswire.comElevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of ObesityOctober 21, 2024 | globenewswire.comSee More Headlines ELAB Stock Analysis - Frequently Asked Questions How have ELAB shares performed this year? Elevai Labs' stock was trading at $1.8282 at the beginning of the year. Since then, ELAB stock has decreased by 98.9% and is now trading at $0.0202. View the best growth stocks for 2024 here. When did Elevai Labs IPO? Elevai Labs (ELAB) raised $6 million in an IPO on Tuesday, November 21st 2023. The company issued 1,500,000 shares at $4.00 per share. Univest Securities served as the underwriter for the IPO. How do I buy shares of Elevai Labs? Shares of ELAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Elevai Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elevai Labs investors own include BIOLASE (BIOL), Conduit Pharmaceuticals (CDT), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), TRACON Pharmaceuticals (TCON), Tempest Therapeutics (TPST) and 22nd Century Group (XXII). Company Calendar Today11/21/2024Next Earnings (Estimated)12/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELAB Previous SymbolNASDAQ:ELAB CUSIPN/A CIK1840563 Webelevaiskincare.com Phone866-794-4940FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,300,000.00 Net Margins-223.41% Pretax Margin-223.37% Return on Equity-124.93% Return on Assets-85.10% Debt Debt-to-Equity Ratio0.06 Current Ratio3.86 Quick Ratio3.40 Sales & Book Value Annual Sales$1.71 million Price / Sales0.25 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book0.05Miscellaneous Outstanding Shares20,810,000Free Float13,107,000Market Cap$424,524.00 OptionableN/A BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:ELAB) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevai Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevai Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.